Analysis and summary of telisotuzumab-EMRELIS cure rate and patient efficacy in clinical application

Telisotuzumab-EMRELIS is a monoclonal antibody drug targeting the c-Met receptor. It is mainly used to treat patients with non-small cell lung cancer (NSCLC) with high expression or amplification of c-Met . By selectively binding to the c-Met protein on the surface of tumor cells, terituzumab can block tumor growth signals, while mediating antibody-dependent cellular cytotoxicity (ADCC) reactions, enhancing the immune system's ability to kill tumors. Clinical trials have shown that terituzumab shows a higher objective response rate in patients with high c-Met expression, providing a new treatment option for advanced or relapsed and refractory NSCLC .

In terms of clinical efficacy, multiple early clinical trials have shown that the objective response rate (ORR) of patients treated with terituzumab combined with standard chemotherapy or targeted therapy is approximately 30% to 45% , and some patients even achieve complete response (CR). In addition, the median progression-free survival (PFS) was prolonged in the combination treatment group, which was statistically superior to the chemotherapy alone group. The patient group with the most obvious efficacy is c-Met high-expression or amplified NSCLC patients who have previously received first-line treatment but have progressed. Such patients have significant tumor shrinkage and symptom improvement after using terituzumab.

Real-world patient feedback also shows that terituzumab can improve quality of life and exercise tolerance in clinical applications. Most patients reported that after several rounds of treatment, symptoms such as dyspnea, fatigue, and cough were relieved, and imaging examinations of some patients showed a significant decrease in tumor burden. Side effects are mainly mild to moderate infusion reactions, fatigue, nausea and rash, most of which can be controlled through symptomatic treatment and dose adjustment without affecting the overall efficacy.

Overall, telisotuzumab (telisotuzumab) -EMRELIS is highly expressed in c-Met NSCLC It has shown positive therapeutic prospects in patients, improving objective response rates, prolonging progression-free survival, and improving patient symptoms and quality of life. Although the cure rate is limited by the type of disease and the patient's underlying conditions, through reasonable individualized medication and combination treatment strategies, terituzumab provides a new clinical option for patients with advanced or drug-resistant non-small cell lung cancer, showing significant practical application value.

Keyword tag:

Telituzumab, Telisotuzumab, EMRELIS, cure rate, efficacy analysis, c-Met, non-small cell lung cancer, NSCLC, objective response rate, progression-free survival, patient feedback, side effects

References:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-telisotuzumab-vedotin-tllv-for-nsclc-high-c-met-protein-overexpression